CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 80 enrolled
Drug / intervention
VOLBELLA® with lidocainedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02176421
NCT02176421N/ACompleted

A Prospective, Open Label Study Evaluating JUVÉDERM® VOLBELLA With Lidocaine Treatment for the Correction of Skin Depressions in the Infra-orbital Area

Allergan·interventional·Posted Jun 27, 2014·Updated Apr 16, 2019

In Brief

A clinical study evaluating VOLBELLA® with lidocaine for Infra-orbital Skin Depressions. Completed, enrolled 80 participants across 1 site.

Detailed Summary

A prospective, open label, study evaluating JUVÉDERM® VOLBELLA with lidocaine treatment for the correction of skin depressions in the infra-orbital area (under the eyes)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 27, 2014
Enrollment StartMay 15, 2014
Primary CompletionAug 18, 2014
Study CompletionJul 3, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 12.0 years ago

Interventions

VOLBELLA® with lidocainedevice

VOLBELLA® with lidocaine administered to correct skin depression during initial treatment and optional top-up treatment 14 days later.